Prof. Mark Levis | ASH 2017 | Overview of FLT3 inhibitors in AML - YouTube
Press Release
Mark Levis, MD, PhD, Discusses a Study on FLT3 Inhibition in R/R AML
ASH 2016: Mark Levis, MD, on CPX-351 Trial Data Presented at This Year's Meeting - Clinical Oncology News
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy - ecancer
Mark Levis, MD, PhD, Discusses a Study on FLT3 Inhibition in R/R AML
Mark Levis Medical Oncology. Baltimore MD
Mark J. Levis | AML Hub
Mark J. Levis, MD, PhD, on Acute Myeloid Leukemia: Gilteritinib in FLT3-Mutated Disease - The ASCO Post
Experimental quizartinib gives bridge to transplant in relapsed AML | MDedge Hematology and Oncology
KU Area Health Education Center - Posts | Facebook
Dr. Mark Levis M.D., Oncologist | Medical Oncology in Baltimore, MD, 21287 | FindATopDoc.com
Dr. Mark Levis – AEROGOLFE
Oncology.TV - Home | Facebook
PDF) Pre-clinical studies of gilteritinib, a next-generation FLT3 inhibitor
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations:
JNCCN 360 - AML - Mark J. Levis, MD, PhD, on AML: First-in-Human Study of an FLT3 Inhibitor
Mark James Levis, M.D., Ph.D., Professor of Oncology | Johns Hopkins Medicine
Mark Levis | ASCO 2018 | Maintenance therapy with gilteritinib in FLT3-ITD+ AML - YouTube
Loop | Mark Levis
Mark J. Levis, MD, PhD, Johns Hopkins University
More Than a Third of High-Risk Leukemia Patients Respond To An Experimental New Drug - 12/21/2012
Mark Levis, MD, PhD, Johns Hopkins University School of Medicine
Rethinking the Treatment of Older Adults With Acute
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia
